- Effect of Progesterone Sequential Therapy on follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) in Spleen Deficiency-induced Perimenopausal Dysfunctional Uterine Bleeding:

Dapeng Li

doi:10.5937/jomb0-53229

Dapeng Li 1

DOI: https://doi.org/10.5937/jomb0-53229

Keywords: Female progesterone sequential therapy; Perimenopausal dysfunctional uterine bleeding; Clinical effect; Curettage treatment, follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2)

Abstract

AIM: Spleen deficiency (SD)-induced perimenopausal dysfunctional uterine bleeding (PDUB) is a common gynecological disease with various clinical treatment options. The objective of this work was to investigate the clinical effect of female progesterone sequential therapy (FPST) on SD-induced PDUB and follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2).

MRTHOD:140 cases of SD-induced PDUB patients were enrolled and randomly rolled into an observation (Obs) group and a control (Ctrl) group, with 70 cases in each. The patients in the Ctrl group were given pure curettage treatment, and those in the Obs group were supplemented with FPST based on the intervention in the Ctrl group.

Result: The therapeutic effects of patients in different groups were compared. The cure rate (CR) and total effective rate (TER) in the Obs group were 84.26% and 97.14%, respectively, which were much higher to those in the Ctrl group (44.29% and 74.29%), showing great differences (P< 0.05). The incidence of adverse reactions in the Obs group and Ctrl group were 4.29% (3/70) and 2.86% (2/70), respectively, exhibiting no great difference (P> 0.05). Additionally, after 3 months of follow-up, the recurrence rate was 1.43% (1/70) in the Obs group, which was much higher to 44.29% (31/70) in the Ctrl group, presenting a remarkable difference with P< 0.05.

Conclusion: In the process of implementing curettage treatment for PDUB, FPST can effectively improve the clinical treatment effect and reduce recurrence rate.

References

1. Goldstein SR, Lumsden MA. Abnormal uterine bleeding in perimenopause. Climacteric, 2017;20(5):414-420.
2. Jewson M, Purohit P, Lumsden MA. Progesterone and abnormal uterine bleeding/menstrual disorders. Best Pract Res Clin Obstet Gynaecol, 2020;69:62-73.
3. Khan R, Sherwani RK, Rana S, Hakim S, Jairajpuri ZS. Clinco-pathological patterns in women with dysfunctional uterine bleeding. Iran J Pathol, 2016;11(1):20-6.
4. Sabbioni L, Zanetti I, Orlandini C, Petraglia F, Luisi S. Abnormal uterine bleeding unrelated to structural uterine abnormalities: management in the perimenopausal period. Minerva Ginecol, 2017;69(1):75-83.
5. Sharma J, Tiwari S. Hysteroscopy in abnormal uterine bleeding vs ultrasonography and histopathology report in perimenopausal and postmenopausal women. JNMA J Nepal Med Assoc, 2016;55(203):26-28.
6. Van den Bosch T, Ameye L, Van Schoubroeck D, Bourne T, Timmerman D. Intra- cavitary uterine pathology in women with abnormal uterine bleeding: a prospective study of 1220 women. Facts Views Vis Obgyn, 2015;7(1):17-24.
7. Doraiswami S, Johnson T, Rao S, Rajkumar A, Vijayaraghavan J, Panicker VK. Study of endometrial pathology in abnormal uterine bleeding. J Obstet Gynaecol India, 2011;61(4):426-30.
8. Chapagain S, Dangal G. Clinical and histopathological presentation of abnormal uterine bleeding in perimenopausal women in tertiary center of nepal. J Nepal Health Res Counc, 2020;18(2):248-252.
9. Kayastha S. Study of endometrial tissue in dysfunctional uterine bleeding. Nepal Med Coll J, 2013;15(1):27-30.
10. Narice BF, Delaney B, Dickson JM. Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam Pract, 2018;19(1):135.
11. Jetley S, Rana S, Jairajpuri ZS. Morphological spectrum of endometrial pathology in middle-aged women with atypical uterine bleeding: a study of 219 cases. J Midlife Health, 2013;4(4):216-20.
12. Pinkerton JV. Pharmacological therapy for abnormal uterine bleeding. Menopause, 2011;18(4):453-61.
13. Abid M, Hashmi AA, Malik B, Haroon S, Faridi N, Edhi MM, Khan M. Clinical pattern and spectrum of endometrial pathologies in patients with abnormal uterine bleeding in Pakistan: need to adopt a more conservative approach to treatment. BMC Womens Health, 2014;14:132.
14. Tang Q, Yang S, Tong J, Li X, Wu J, Wang S, Zhang J, Chen Y, Xu X. Hemostasis and uterine contraction promoting effect of the extract from drugs in the Zi-Yin-Tiao-Jing granule, a traditional Chinese compound preparation. J Ethnopharmacol, 2018;211:278-284.
15. Song Y, Xu W, Chatooah ND, Chen J, Huang Y, Chen P, Lan Y, Li C, Ying Q, Ma L, Zhou J. Comparison of low dose versus ultra-low dose hormone therapy in menopausal symptoms and quality of life in perimenopause women. Gynecol Endocrinol, 2020;36(3):252-256.
16. Shapley M, Blagojevic-Bucknall M, Jordan KP, Croft PR. The epidemiology of self-reported intermenstrual and postcoital bleeding in the perimenopausal years. BJOG, 2013;120(11):1348-55.
17. Nazim F, Hayat Z, Hannan A, Ikram U, Nazim K. Role of transvaginal ultrasound in identifying endometrial hyperplasia. J Ayub Med Coll Abbottabad, 2013;25(1-2):100-2.
18. Rezk M, Masood A, Dawood R. Perimenopausal bleeding: patterns, pathology, response to progestins and clinical outcome. J Obstet Gynaecol, 2015;35(5):517-21.
19. Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, Dehghani-Firoozabadi Z, Teimoori S, Chiti Z, Miratashi-Yazdi A, Dehghani A. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol, 2013;40(3):421-4.
20. Gibson CJ, Bromberger JT, Weiss GE, Thurston RC, Sowers M, Matthews KA. Negative attitudes and affect do not predict elective hysterectomy: a prospective analysis from the Study of Women's Health Across the Nation. Menopause, 2011;18(5):499-507.
21. Gao M, Goodman A, Mishra G, Koupil I. Associations of birth characteristics with perimenopausal disorders: a prospective cohort study. J Dev Orig Health Dis, 2019;10(2):246-252.
22. Grulović B, Pucelj MR, Krnić M, Kokić V. Impact of prostaglandin F2-alpha and tumor necrosis factor-alpha (TNF-alpha) on pain in patients undergoing thermal balloon endometrial ablation. Coll Antropol, 2013;37(4):1185-90.
23. Han J, Wang X, Lv W, Tian RY, Guan L. Comparison between direct use and PLGA nanocapsules containing drug of traditional Chinese medicine, Tiaojing Zhixue, in treatment of dysfunctional uterine bleeding. Cell Mol Biol (Noisy-le-grand), 2021;67(3):138-142.
24. Basyigit S, Sapmaz F, Kefeli A, Yeniova AO, Asilturk Z, Hokkaomeroglu M, Uzman M, Nazligul Y. Increasing antibiotic resistance is the main cause for the failure of helicobacter pylori eradication: comparison of three trusted treatment pro-tocols. Acta Med Mediterr, 2016;32:297.
25. Oo TH. Nonhematological manifestations of pernicious anemia. Discov Med, 2022;34(173):165-169.
26. Chang C, Shang Y, Gao Y, Shang M, Wang L, Li H. Clinical features, treatment, and prognosis of 16 breast cancer patients with ocular metastases. Cell Mol Biol (Noisy-le-grand). 2022;67(5):363-70. https://www.cellmolbiol.org/index.php/CMB/article/view/4133
27. Guan L, Xue L, Chu J, Xue J, Zhang S, Zhu L. Effect of Tiaojingzhixue Fang on the expression of sex hormone and endometrial tissue mRNA in perimenopausal patients with abnormal uterine bleeding. Cell Mol Biol (Noisy-le-grand). 2022;67(5):317-23. https://www.cellmolbiol.org/index.php/CMB/article/view/4127
28. Liang XH, Li HL, Zhou XC, Zhang M. Cancer-associated fibroblasts promote the proliferationand migration of endometrial carcinoma cells by enhancing ferroptosis resistance. J Biol Regulat Homeost Agent, 2022;36(3):2131-2138.